{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:37Z","timestamp":1792783237902,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371411"],"award-info":[{"award-number":["82371411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Medical Award Foundation Award for Medical Sciences","award":["YXJL-2024-0387-0085"],"award-info":[{"award-number":["YXJL-2024-0387-0085"]}],"id":[{"id":"https:\/\/ror.org\/03gzgaa54","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Life Oasis Public Service Center","award":["P119-003"],"award-info":[{"award-number":["P119-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00415-026-13695-3","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:43:16Z","timestamp":1771263796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations\/worsening: multicenter real-world retrospective study"],"prefix":"10.1007","volume":"273","author":[{"given":"Jing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"26","key":"13695_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375(26):2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"issue":"10","key":"13695_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"13695_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000512077","volume":"84","author":"AR Abuzinadah","year":"2021","unstructured":"Abuzinadah AR, Alanazy MH, Butt NS, Barohn RJ, Dimachkie MM (2021) Exacerbation rate in generalized myasthenia gravis and its predictors. Eur Neurol 84(1):43\u201348. https:\/\/doi.org\/10.1159\/000512077","journal-title":"Eur Neurol"},{"issue":"3","key":"13695_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10072-022-06493-y","volume":"44","author":"J Chen","year":"2023","unstructured":"Chen J, Li S, Feng L, Wang H, Huang X, Feng H (2023) Nomogram for the acute exacerbation of acetylcholine receptor antibody-positive generalized myasthenia gravis. Neurol Sci 44(3):1049\u20131057. https:\/\/doi.org\/10.1007\/s10072-022-06493-y","journal-title":"Neurol Sci"},{"issue":"7","key":"13695_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/03007995.2024.2353381","volume":"40","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Pesa J, Boonmak P et al (2024) Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events. Curr Med Res Opin 40(7):1145\u20131153. https:\/\/doi.org\/10.1080\/03007995.2024.2353381","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"13695_CR6","doi-asserted-by":"publisher","first-page":"e16180","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, Cort\u00e9s-Vicente E, Schneider-Gold C (2024) Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol 31(6):e16180. https:\/\/doi.org\/10.1111\/ene.16180","journal-title":"Eur J Neurol"},{"issue":"7","key":"13695_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acn3.51792","volume":"10","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang F, Long Z et al (2023) Mortality of myasthenia gravis: a national population-based study in China. Ann Clin Transl Neurol 10(7):1095\u20131105. https:\/\/doi.org\/10.1002\/acn3.51792","journal-title":"Ann Clin Transl Neurol"},{"key":"13695_CR8","doi-asserted-by":"publisher","first-page":"767961","DOI":"10.3389\/fneur.2021.767961","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Tan Y, Shi J, Li K, Yan J, Guan Y (2021) Patients with myasthenia gravis with acute onset of dyspnea: predictors of progression to myasthenic crisis and prognosis. Front Neurol 12:767961. https:\/\/doi.org\/10.3389\/fneur.2021.767961","journal-title":"Front Neurol"},{"key":"13695_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-019-0023-3","volume":"1","author":"H Stetefeld","year":"2019","unstructured":"Stetefeld H, Schroeter M (2019) SOP myasthenic crisis. Neurol Res Pract 1:19. https:\/\/doi.org\/10.1186\/s42466-019-0023-3","journal-title":"Neurol Res Pract"},{"issue":"4","key":"13695_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"issue":"6","key":"13695_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40120-025-00711-3","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group. Ann Neurol 41(6):789\u2013796. https:\/\/doi.org\/10.1007\/s40120-025-00711-3","journal-title":"Ann Neurol"},{"issue":"3","key":"13695_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.52.3.629","volume":"52","author":"AI Qureshi","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS et al (1999) Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52(3):629\u2013632. https:\/\/doi.org\/10.1212\/WNL.52.3.629","journal-title":"Neurology"},{"issue":"23","key":"13695_CR13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017\u20132023. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e5505","journal-title":"Neurology"},{"key":"13695_CR14","doi-asserted-by":"publisher","first-page":"109058","DOI":"10.1016\/j.clim.2022.109058","volume":"241","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huan X, Jiao K et al (2022) Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol 241:109058. https:\/\/doi.org\/10.1016\/j.clim.2022.109058","journal-title":"Clin Immunol"},{"issue":"5","key":"13695_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023) Efgartigimod alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs 37(5):467\u2013473. https:\/\/doi.org\/10.1007\/s40263-023-01000-z","journal-title":"CNS Drugs"},{"issue":"7","key":"13695_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"13695_CR17","doi-asserted-by":"publisher","first-page":"1418503","DOI":"10.3389\/fimmu.2024.1418503","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Wang H, Huan X et al (2024) Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol 15:1418503. https:\/\/doi.org\/10.3389\/fimmu.2024.1418503","journal-title":"Front Immunol"},{"key":"13695_CR18","doi-asserted-by":"publisher","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","volume":"395","author":"Y Hong","year":"2024","unstructured":"Hong Y, Gao L, Huang SQ et al (2024) Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series. J Neuroimmunol 395:578431. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578431","journal-title":"J Neuroimmunol"},{"issue":"1","key":"13695_CR19","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","volume":"14","author":"J Ma","year":"2024","unstructured":"Ma J, Zhang H, Zhao J et al (2024) Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis. Sci Rep 14(1):28394. https:\/\/doi.org\/10.1038\/s41598-024-79918-7","journal-title":"Sci Rep"},{"issue":"8","key":"13695_CR20","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W et al (2024) Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol 11(8):2212\u20132221. https:\/\/doi.org\/10.1002\/acn3.52142","journal-title":"Ann Clin Transl Neurol"},{"key":"13695_CR21","doi-asserted-by":"publisher","first-page":"175628642413013","DOI":"10.1177\/17562864241301361","volume":"17","author":"M Menacher","year":"2024","unstructured":"Menacher M, Ellssel M, Kwiedor I, Naumann M, Bayas A (2024) Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis-a case series. Ther Adv Neurol Disord 17:17562864241301360. https:\/\/doi.org\/10.1177\/17562864241301361","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"13695_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12883-024-03804-y","volume":"24","author":"H Ohara","year":"2024","unstructured":"Ohara H, Kikutsuji N, Iguchi N, Kinoshita M (2024) Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report. BMC Neurol 24(1):292. https:\/\/doi.org\/10.1186\/s12883-024-03804-y","journal-title":"BMC Neurol"},{"issue":"6","key":"13695_CR23","doi-asserted-by":"publisher","first-page":"e00730","DOI":"10.1016\/j.neurot.2025.e00730","volume":"22","author":"R Guo","year":"2025","unstructured":"Guo R, Sun C, Huang XX et al (2025) Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: a retrospective cohort study. Neurotherapeutics 22(6):e00730. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00730","journal-title":"Neurotherapeutics"},{"issue":"1","key":"13695_CR24","doi-asserted-by":"publisher","first-page":"1696976","DOI":"10.3389\/fneur.2025.1696976","volume":"16","author":"FY Shi","year":"2026","unstructured":"Shi FY, Wang J, Chen JX et al (2026) Add-on efgartigimod in myasthenic crisis: a promising treatment option. Front Neurol 16(1):1696976. https:\/\/doi.org\/10.3389\/fneur.2025.1696976","journal-title":"Front Neurol"},{"key":"13695_CR25","unstructured":"Smith AG (2025) Hospitalization outcomes after efgartigimod initiation in patients with myasthenia gravis. American academy of neurology (AAN) annual meeting, San Diego, CA"},{"issue":"4","key":"13695_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI (2014) Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 15(4):167\u2013178. https:\/\/doi.org\/10.1097\/CND.0000000000000034","journal-title":"J Clin Neuromuscul Dis"},{"issue":"12","key":"13695_CR27","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","volume":"84","author":"B Keung","year":"2013","unstructured":"Keung B, Robeson KR, DiCapua DB et al (2013) Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 84(12):1407\u20131409. https:\/\/doi.org\/10.1136\/jnnp-2012-303664","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"13695_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65(6):630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"issue":"5","key":"13695_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM (2011) MG-ADL: still a relevant outcome measure. Muscle Nerve 44(5):727\u2013731. https:\/\/doi.org\/10.1002\/mus.22140","journal-title":"Muscle Nerve"},{"issue":"5","key":"13695_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"issue":"2","key":"13695_CR31","doi-asserted-by":"publisher","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V et al (2024) Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study. Neurology 102(2):e207937. https:\/\/doi.org\/10.1212\/WNL.0000000000207937","journal-title":"Neurology"},{"issue":"4","key":"13695_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","volume":"81","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y et al (2024) Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol 81(4):336\u2013345. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0044","journal-title":"JAMA Neurol"},{"issue":"4","key":"13695_CR33","doi-asserted-by":"publisher","first-page":"e70391","DOI":"10.1111\/cns.70391","volume":"31","author":"SJ Hao","year":"2025","unstructured":"Hao SJ, Ruan Z, Guo RJ et al (2025) Efficacy and safety of Efgartigimod for patients with myasthenia gravis in a real-world cohort of 77 patients. CNS Neurosci Ther 31(4):e70391. https:\/\/doi.org\/10.1111\/cns.70391","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"13695_CR34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan RS, Yang H et al (2022) Therapeutic effects of Batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther 11(2):815\u2013834. https:\/\/doi.org\/10.1007\/s40120-022-00345-9","journal-title":"Neurol Ther"},{"issue":"5","key":"13695_CR35","doi-asserted-by":"publisher","first-page":"e200455","DOI":"10.1212\/nxi.0000000000200455","volume":"12","author":"MC Tarasco","year":"2025","unstructured":"Tarasco MC, Rinaldi E, Frangiamore R et al (2025) Unknown immunoregulatory effects of FcRn inhibition by Efgartigimod in myasthenia gravis: a new mechanism of action beyond IgG reduction. Neurol Neuroimmunol Neuroinflamm 12(5):e200455. https:\/\/doi.org\/10.1212\/nxi.0000000000200455","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"13695_CR36","doi-asserted-by":"publisher","first-page":"e1426","DOI":"10.1212\/WNL.0000000000010209","volume":"95","author":"M Tomschik","year":"2020","unstructured":"Tomschik M, Hilger E, Rath J et al (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95(10):e1426\u2013e1436. https:\/\/doi.org\/10.1212\/WNL.0000000000010209","journal-title":"Neurology"},{"issue":"1","key":"13695_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Stascheit F, Eckert C et al (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation 19(1):89. https:\/\/doi.org\/10.1186\/s12974-022-02448-4","journal-title":"J Neuroinflammation"},{"issue":"4","key":"13695_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.27659","volume":"66","author":"I Lee","year":"2022","unstructured":"Lee I, Leach JM, Aban I, McPherson T, Duda PW, Cutter G (2022) One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG patient registry. Muscle Nerve 66(4):411\u2013420. https:\/\/doi.org\/10.1002\/mus.27659","journal-title":"Muscle Nerve"},{"key":"13695_CR39","doi-asserted-by":"publisher","first-page":"175628642210805","DOI":"10.1177\/17562864221080520","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Yang S, Dong X et al (2022) Factors affecting minimal manifestation status induction in myasthenia gravis. Ther Adv Neurol Disord 15:17562864221080520. https:\/\/doi.org\/10.1177\/17562864221080520","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"13695_CR40","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","volume":"55","author":"K Utsugisawa","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T et al (2017) Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55(6):794\u2013801. https:\/\/doi.org\/10.1002\/mus.25397","journal-title":"Muscle Nerve"},{"issue":"5","key":"13695_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22(5):395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"issue":"12","key":"13695_CR42","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"13695_CR43","doi-asserted-by":"publisher","first-page":"114603","DOI":"10.1016\/j.intimp.2025.114603","volume":"154","author":"J Chen","year":"2025","unstructured":"Chen J, Zhu X, Zhou H et al (2025) Efficacy of multi-cycle efgartigimod in achieving minimal symptom expression in myasthenia gravis: a comparative multi-center study. Int Immunopharmacol 154:114603. https:\/\/doi.org\/10.1016\/j.intimp.2025.114603","journal-title":"Int Immunopharmacol"},{"key":"13695_CR44","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"13695_CR45","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40120-025-00711-3","volume":"14","author":"A Ting","year":"2025","unstructured":"Ting A, Park M, Sangha O et al (2025) Risk of exacerbation and level of healthcare resource utilization in myasthenia gravis assessed by myasthenia gravis activities of daily living score. Neurol Ther 14(2):575\u2013591. https:\/\/doi.org\/10.1007\/s40120-025-00711-3","journal-title":"Neurol Ther"},{"issue":"6","key":"13695_CR46","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/acn3.70051","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, Claeys KG, Bril V et al (2025) ADAPT NXT: fixed cycles or every-other-week IV efgartigimod in generalized myasthenia gravis. Ann Clin Transl Neurol 12(6):1162\u20131170. https:\/\/doi.org\/10.1002\/acn3.70051","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13695-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:02:12Z","timestamp":1773784932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13695-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13695"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13695-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors claim that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study has been approved by the Clinical Investigation Committee at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval Number: TJ-IRB202407056) and conformed to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written or oral informed consent for the publication of this study was obtained from the patient and\/or their family.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"146"}}